US FDA approves Vertex's non-opioid painkiller-February 2024-www.financetom.com

US FDA approves Vertex's non-opioid painkiller

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves Vertex's non-opioid painkiller

Jan 30, 2025 3:06 PM

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex

Pharmaceuticals' ( VRTX ) drug to treat acute pain, the health regulator said on Thursday,

offering an alternative to addictive opioid painkillers that have fueled a national crisis.

Previous page： PharmaTher's Sairiyo Therapeutics Gets OK to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine) Next page： Laramide Resources Says Australian Drilling Proceeding as Planned

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

PharmaTher's Sairiyo Therapeutics Gets OK to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)

Aug 19, 2024

08:04 AM EDT, 08/19/2024 (MT Newswires) -- PharmaTher Holdings Ltd. ( PHRRF ) , a specialty pharmaceutical company, announced Monday Sairiyo Therapeutics Inc., a company that is 49% owned by PharmaTher ( PHRRF ) and 51% owned by PharmaDrug Inc. ( LMLLF ) , has received approval by the Australian Human Research Ethics Committee to initiate a first-in-human Phase 1...

Laramide Resources Says Australian Drilling Proceeding as Planned

Aug 19, 2024

08:05 AM EDT, 08/19/2024 (MT Newswires) -- Laramide Resources ( LMRXF ) , a uranium mine development and exploration company with assets in the United States and Australia, on Monday provided an update on its drilling activities at the Westmoreland Uranium Project in Queensland, Australia. This season's exploration drilling campaign is comprised of up to 12,000 metres of diamond and...

Tonix Pharmaceuticals Holding's Q2 Loss Narrows, Revenue Rises

Aug 19, 2024

08:01 AM EDT, 08/19/2024 (MT Newswires) -- Tonix Pharmaceuticals Holding ( TNXP ) reported a Q2 loss Monday of $19.28 per diluted share, narrowing from a loss of $49.23 a year earlier. Three analysts polled by Capital IQ expected a loss of $3.27. Revenue for the quarter ended June 30 was $2.21 million, compared with no revenue a year earlier....

Tiziana Life Sciences Names Ivor Elrifi as CEO

Aug 19, 2024

08:05 AM EDT, 08/19/2024 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Monday it has named Ivor Elrifi as chief executive officer, effective immediately. He succeeds Gabriele Cerrone, who served as chief executive and will remain as executive chairman of the board. Elrifi previously served as global head of the patent group at Cooley and global head of...